2. Academic Validation
  3. Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity

Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity

  • J Med Chem. 2024 Mar 11. doi: 10.1021/acs.jmedchem.4c00102.
Liu Liu 1 2,  Honghan Zhang 1,  Jie Hou 1,  Yuying Zhang 1 3,  Luosen Wang 1,  Shijun Wang 1,  Zhiying Yao 1,  Tao Xie 1,  Xiaoan Wen 1 2,  Qinglong Xu 1 2,  Liang Dai 1 2,  Zhiqi Feng 1 2,  Pu Zhang 4,  Yaojun Wu 4,  Hongbin Sun 1 2,  Jun Liu 1 3,  Haoliang Yuan 1 2
Affiliations

Affiliations

  • 1 Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
  • 2 Chongqing Innovation Institute of China Pharmaceutical University, Chongqing 401135, China.
  • 3 New Drug Screening Center, China Pharmaceutical University, Nanjing 210009, China.
  • 4 Jiangsu Flag Chemical Industry Co., Ltd., Nanjing 211500, China.
PMID: 38465588 DOI: 10.1021/acs.jmedchem.4c00102
Abstract

Programmed death-ligand 1 (PD-L1) has surfaced as a promising therapeutic target for various cancers due to its pivotal role in facilitating tumor immune evasion. Herein, we report a series of novel small-molecule PD-L1 inhibitors exhibiting remarkable inhibitory activity against the PD-1/PD-L1 interaction (X18: IC50 = 1.3 nM) and reinstating the suppressive effect of PD-L1 on T cells (X18: EC50 = 152.8 nM). Crystallographic studies revealed the binding mode of X18 and PD-L1. Through a rational prodrug design approach, we have successfully optimized the oral pharmacokinetic properties of X22, effectively addressing the poor oral pharmacokinetic profile of PD-L1 small-molecule inhibitors. Notably, X22 demonstrated significant antitumor efficacy in murine models of MC38 and CT26 colon Cancer through the upregulation of tumor infiltration and cytotoxicity of CD8+ T cells partially. These findings offer promising prospects for the advancement of PD-L1 inhibitors as innovative agents in Cancer Immunotherapy.

Figures
Products